SCHEMBL19999801

SCHEMBL19999801

CN(C(=O)[C@@H](N)Cc1cc(F)cc(F)c1)c1ccc(CC(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CIT O14578 1/20 0.41
MAOB P27338 1/20 0.37
CYP3A4 P08684 3/20 0.36
ALOX15 P16050 3/20 0.36
HIF1A Q16665 3/20 0.36
PTGS1 P23219 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ABCB11 O95342 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
ACHE P22303 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180281 0.88 CIT (0.39) CITMAOBCYP3A4ALOX15HIF1A
SCHEMBL19962121 0.86 CIT (0.38) CITMAOBCYP3A4ALOX15HIF1A
SCHEMBL18180401 0.86 CIT (0.39) CITCYP3A4ALOX15HIF1APTGS1
SCHEMBL18317595 0.86 CIT (0.39) CITCYP3A4ALOX15HIF1APTGS1
SCHEMBL21993366 0.86 MAOB (0.40) MAOBALDH1A1MEN1LMNAKMT2A
SCHEMBL19999807 0.85 CIT (0.39) CITMAOBAKT1AKT2AKT3
SCHEMBL19999805 0.84 MAOB (0.38) CITMAOBALDH1A1SMN1; SMN2KDM4E
SCHEMBL18180177 0.84 BMP1 (0.41) CITMAOBALDH1A1SMN1; SMN2TPH1
SCHEMBL19962118 0.84 NR1H4 (0.41) CITALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL18317286 0.84 BMP1 (0.41) CITMAOBALDH1A1SMN1; SMN2TPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H CIT 1337/4885MAOB 2183/4885CYP3A4 620/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H CIT 1337/4885MAOB 2183/4885CYP3A4 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.